Neuroblastoma is the most common extracranial solid tumor in childhood. The aggressiveness of neuroblastoma is determined by tumor-promoting and tumor-suppres¬sive mechanisms that are inactivated or activated, respectively. We therefore investigate the interaction of oncogenes such as MYCN, BIRC5 and LDHA/B with dysfunctional tumor suppressors in the genesis, progression and aerobic glycolysis (Warburg effect) of neuroblastoma. To this end, we use cellular and molecular biology methods, transgenic and xenotransplant mouse models, and bioinformatic tools. We are translating the results of this preclinical work into establishing prognostic markers and liquid biopsy for neuroblastoma patients.

Specificity and efficacy are major challenges in targeted tumor therapy. We develop novel approaches to address these challenges in neuroblastoma and acute lymphoblastic leukemia. To this end, we investigate small molecules that intervene specifically in signaling pathways crucial for neuroblastoma. In addition, we explore oncolytic measles virus against ALL. Our aim is to translate these novel preclinical therapies to the patient with neuroblastoma or ALL.